Search companies

Live

Tuesday, 17 November 2026 · 583 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

INOVIQ Sets Staged Path To Advance Ovarian Cancer Test Toward US Readiness

INOVIQ Limited (IIQ) · Health care

IIQ: $0.135 -1.82% · MC: $18M

INOVIQ says an independent US review found sample collection and handling differences were the main source of variability in its OC2200 study, and it has begun a staged program to optimise and verify its EXO-OC ovarian cancer test, targeting US laboratory test readiness by the first half of 2028. The company reported A$8 million in cash at quarter-end and said it received a further approximately A$2 million in R&D tax incentives after quarter-end; it is prioritising the test and its CAR-exosome program. Chairman Peter Gunzburg has taken on the interim Executive Chair role following Dr Leearne Hinch’s departure.

Source announcements: 2026-10-29 08:40 to 2026-10-29 08:40 Sydney time
Story updated 2026-10-29 08:45 Sydney time
SourcesQuarterly Activities Report and Appendix 4C - September 2026
Comments